ACHV stock touches 52-week low at $2.81 amid market challenges

Published 12/03/2025, 15:26
ACHV stock touches 52-week low at $2.81 amid market challenges

OncoGenex Pharmaceuticals Inc. (NASDAQ:ACHV) stock has reached a 52-week low, dipping to $2.81, as the company faces a tumultuous market environment. According to InvestingPro data, the company’s volatility is reflected in its beta of 1.68, indicating higher market sensitivity than average. This latest price level reflects a significant downturn over the past year, with the stock experiencing a 1-year change of -35.97%. With a market capitalization of $98.85 million, investors are closely monitoring ACHV as it navigates through the pressures of the biopharmaceutical industry. InvestingPro analysis reveals concerning trends, with 4 analysts recently revising earnings downward and the company quickly burning through cash, though it maintains a strong current ratio of 6.78. The 52-week low serves as a critical point of interest for both current shareholders and potential investors, as they consider the company’s performance and future prospects amidst a challenging economic landscape. Discover 10+ additional exclusive insights and detailed analysis in the comprehensive Pro Research Report, available on InvestingPro.

In other recent news, Achieve Life Sciences reported fourth quarter earnings that did not meet analyst expectations, with a quarterly loss of $0.36 per share, which was $0.02 below the consensus estimate. The company disclosed total operating expenses of $12.2 million and a net loss of $12.4 million for the quarter. Achieve Life Sciences ended the year with $34.4 million in cash, cash equivalents, and marketable securities. Despite the earnings miss, the company plans to submit a new drug application for cytisinicline to the U.S. Food and Drug Administration by the end of the second quarter of 2025. Achieve Life Sciences has completed enrollment in its ORCA-OL long-term exposure trial, reaching the required 300 participants for the NDA submission. The company also reported positive outcomes from two data safety monitoring committee reviews of the ORCA-OL trial, with no safety concerns identified. Additionally, Achieve Life Sciences appointed two new board members and a new Chief Financial Officer to support its strategic initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.